LYMPHIR added to NCCN Guidelines for CTCL treatment

Citius Pharmaceuticals, Inc.

NCCN Category 2A recommendation supports LYMPHIR as option for relapsed/refractory CTCL after at least one prior systemic therapy.
LYMPHIR targets IL-2 receptor on malignant T-cells; FDA approved based on Phase 3 study results.
CEO says NCCN inclusion could aid physician adoption and ease reimbursement, potentially expanding CMS coverage.
Citius Pharma (CTXR) and Citius Oncology (CTOR) jointly announced the guideline addition on Sep 5, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.